Nkarta Inc NKTX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-07-10 |
| Shares Out. | 71,550,000 |
| Website | nkartatx.com/ ↗ |
| Phone | 19254071049 |
| Employees | 108 |
| Net Income | -$28.4M |
| Free Cash Flow | -$88.4M |
| Total Assets | $372.1M |
| Total Liabilities | $86.2M |
| Equity | $285.9M |
About Nkarta Inc
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Nkarta Inc is a publicly traded company under the ticker symbol NKTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)